This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Does Alpine Immune Sciences, Inc. (ALPN) Have the Potential to Rally 25.38% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.4% in Alpine Immune Sciences, Inc. (ALPN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Alpine Immune (ALPN) Stock Up 19% MTD, Will the Uptick Continue?
by Zacks Equity Research
Alpine Immune has been riding on positive momentum surrounding its under-development drug program.
Alpine Immune Sciences, Inc. (ALPN) Soars 5.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Neurocrine Biosciences (NBIX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -403.85% and 1.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -51.85% and 73.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in Alpine (ALPN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Alpine (ALPN) stock based on the movements in the options market lately.
Alpine Immune Sciences, Inc. (ALPN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -320% and 59.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of 0% and 87.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Fresh Tracks Therapeutics (FRTX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fresh Tracks Therapeutics (FRTX) delivered earnings and revenue surprises of -9.52% and 56.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 5.26% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Revised)
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -30.43% and 18.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Alpine Immune Sciences, Inc. (ALPN): Can Its 7.5% Jump Turn into More Strength?
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Alpine Immune Sciences, Inc. (ALPN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After Plunging 23.2% in 4 Weeks, Here's Why the Trend Might Reverse for Alpine Immune Sciences, Inc. (ALPN)
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Esperion Therapeutics (ESPR) Moves 6.5% Higher: Will This Strength Last?
by Zacks Equity Research
Esperion Therapeutics (ESPR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Alpine Immune Sciences, Inc. (ALPN) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stevanato Group (STVN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Stevanato (STVN) delivered earnings and revenue surprises of 8.33% and 5.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Revolution Medicines, Inc. (RVMD) Surges 5.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Alpine Immune Sciences, Inc. (ALPN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -47.06% and 2.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 12% and 12.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Endo International (ENDP) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Endo (ENDP) delivered earnings and revenue surprises of 50% and 1.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Alpine Immune Sciences, Inc. (ALPN) Soars 6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -100% and 45.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Alpine Immune Sciences, Inc. (ALPN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Surprise Coming for Alpine Immune Sciences (ALPN) This Earnings Season?
by Zacks Equity Research
Alpine Immune Sciences (ALPN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.